Company registration number 12633979 (England and Wales)
PYSER HEALTH LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2025
PAGES FOR FILING WITH REGISTRAR
PYSER HEALTH LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 6
PYSER HEALTH LIMITED
BALANCE SHEET
AS AT
31 MAY 2025
31 May 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
4
-
0
195,080
Current assets
Debtors
5
178
3,308
Cash at bank and in hand
2,222
2,225
2,400
5,533
Creditors: amounts falling due within one year
6
(1,182)
(153,606)
Net current assets/(liabilities)
1,218
(148,073)
Total assets less current liabilities
1,218
47,007
Creditors: amounts falling due after more than one year
7
(2,024,829)
(1,723,878)
Net liabilities
(2,023,611)
(1,676,871)
Capital and reserves
Called up share capital
8
1,000
1,000
Profit and loss reserves
(2,024,611)
(1,677,871)
Total equity
(2,023,611)
(1,676,871)

For the financial year ended 31 May 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 21 May 2026 and are signed on its behalf by:
Mr J A Steinberg
Director
Company registration number 12633979 (England and Wales)
PYSER HEALTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2025
- 2 -
1
Accounting policies
Company information

Pyser Health Limited is a private company limited by shares incorporated in England and Wales. The registered office is 3rd Floor, 7-10 Chandos Street, London, WIG 9DQ.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

Pyser Health Limited is wholly owned subsidiary of Elgin Partners Limited

Elgin Partners Limited has taken advantage of the exemption under S399 of the Companies Act 2006 not to prepare consolidated accounts on the basis that it is a parent of a small group.

1.2
Going concern

At the time of approving the financial statements, due to ongoing support from the parent company the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the the going concern basis of accounting in preparing the financial statements.true

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold improvements
20% straight line
Plant and equipment
20% straight line
Computer equipment
25% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

PYSER HEALTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2025
1
Accounting policies
(Continued)
- 3 -

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted. If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.5
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.6
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

PYSER HEALTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2025
1
Accounting policies
(Continued)
- 4 -
Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future paymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. A m ounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.7
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.8
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the director is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
0
0
PYSER HEALTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2025
- 5 -
4
Tangible fixed assets
Land and buildings
Plant and machinery etc
Total
£
£
£
Cost
At 1 June 2024 and 31 May 2025
462,765
907,035
1,369,800
Depreciation and impairment
At 1 June 2024
462,765
711,955
1,174,720
Depreciation charged in the year
-
0
195,080
195,080
At 31 May 2025
462,765
907,035
1,369,800
Carrying amount
At 31 May 2025
-
0
-
0
-
0
At 31 May 2024
-
0
195,080
195,080
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Other debtors
178
3,308
6
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
331
22,755
Other creditors
851
130,851
1,182
153,606
7
Creditors: amounts falling due after more than one year
2025
2024
£
£
Amounts owed to group undertakings
1,048,829
877,878
Other creditors
976,000
846,000
2,024,829
1,723,878
8
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
1,000
1,000
1,000
1,000
PYSER HEALTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2025
- 6 -
9
Parent company

The company is a wholly owned subsidiary of Elgin Partners Limited whose registered office is 3rd floor, 7-10 Chandos Street London, W1G 9DQ

Elgin Partners Limited is a parent of a small group and has taken advantage of the exemptions under section 399 of the Companies Act 2006 not to prepare consolidated accounts.

2025-05-31 2024-06-01 false false false 21 May 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity JA Steinberg R G M Coulson 12633979 2024-06-01 2025-05-31 12633979 2025-05-31 12633979 2024-05-31 12633979 core:LandBuildings 2025-05-31 12633979 core:OtherPropertyPlantEquipment 2025-05-31 12633979 core:LandBuildings 2024-05-31 12633979 core:OtherPropertyPlantEquipment 2024-05-31 12633979 core:CurrentFinancialInstruments core:WithinOneYear 2025-05-31 12633979 core:CurrentFinancialInstruments core:WithinOneYear 2024-05-31 12633979 core:Non-currentFinancialInstruments core:AfterOneYear 2025-05-31 12633979 core:Non-currentFinancialInstruments core:AfterOneYear 2024-05-31 12633979 core:CurrentFinancialInstruments 2025-05-31 12633979 core:CurrentFinancialInstruments 2024-05-31 12633979 core:Non-currentFinancialInstruments 2025-05-31 12633979 core:Non-currentFinancialInstruments 2024-05-31 12633979 core:ShareCapital 2025-05-31 12633979 core:ShareCapital 2024-05-31 12633979 core:RetainedEarningsAccumulatedLosses 2025-05-31 12633979 core:RetainedEarningsAccumulatedLosses 2024-05-31 12633979 core:ShareCapitalOrdinaryShareClass1 2025-05-31 12633979 core:ShareCapitalOrdinaryShareClass1 2024-05-31 12633979 bus:Director1 2024-06-01 2025-05-31 12633979 core:LandBuildings core:LongLeaseholdAssets 2024-06-01 2025-05-31 12633979 core:PlantMachinery 2024-06-01 2025-05-31 12633979 core:ComputerEquipment 2024-06-01 2025-05-31 12633979 2023-06-01 2024-05-31 12633979 core:LandBuildings 2024-05-31 12633979 core:OtherPropertyPlantEquipment 2024-05-31 12633979 2024-05-31 12633979 core:LandBuildings 2024-06-01 2025-05-31 12633979 core:OtherPropertyPlantEquipment 2024-06-01 2025-05-31 12633979 bus:OrdinaryShareClass1 2024-06-01 2025-05-31 12633979 bus:OrdinaryShareClass1 2025-05-31 12633979 bus:OrdinaryShareClass1 2024-05-31 12633979 bus:PrivateLimitedCompanyLtd 2024-06-01 2025-05-31 12633979 bus:SmallCompaniesRegimeForAccounts 2024-06-01 2025-05-31 12633979 bus:FRS102 2024-06-01 2025-05-31 12633979 bus:AuditExemptWithAccountantsReport 2024-06-01 2025-05-31 12633979 bus:Director2 2024-06-01 2025-05-31 12633979 bus:FullAccounts 2024-06-01 2025-05-31 xbrli:pure xbrli:shares iso4217:GBP